

## Malignant Hematology Areas of Interest

### (Investigator Initiated Studies and Research Collaborations)

#### REGN1979 (CD20xCD3) odronextamab

**Non-interventional proposals:**

- Investigating tumor and immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

**Interventional proposals:**

- Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL.
- Sequencing Odronextamab in the treatment paradigm for the treatment of B-NHL
- Investigating Odronextamab in hard-to-treat, medically unaddressed, and rare populations with B-Cell malignancies in high unmet medical needs for treatment.
- Alternative regimens, including new outpatient administration and outpatient monitoring protocols that may alleviate patient logistical barriers to treatment.
- Predictors of response and/or (primary or acquired) resistance to Odronextamab in the treatment of b-NHL

(5.0, 27Feb2024)

#### REGN5458 (BCMA x CD3 bispecific antibody)

**Non-interventional proposals in Plasma Cell Dyscrasias exploring:**

- Biomarkers leading to better characterization, management, and treatment options
  - BCMA expression pre- and post-treatment (standard of care agents or novel agents)
  - Early disease progression and/or mechanisms of resistance
  - T cell phenotyping in biopsy and aspirate
  - Plasma cell markers associated with progression/resistance to standard of care
  - Immune subset characterization including T cell suppressive mechanisms
  - Biomarkers for future therapeutic target development
  - Biomarkers of Plasma Cell Dyscrasias
- Models to assess functional immune responsiveness to BCMA x CD3
- Experimental models to explore novel combinations with BCMA x CD3

**Interventional proposals:**

- Studies to explore linvoseltamab as **monotherapy** in Multiple Myeloma in lines earlier than in Triple Class Refractory
  - Treatment sequencing strategies
  - Special patient (sub) populations based on patient demographics and disease characteristics
  - Alternative mitigation procedures to manage bispecific adverse events
  - Biomarker signatures in linvoseltamab-treated patients
- No linvoseltamab combination therapy proposals will be considered at this time.

(v4.1, 13Feb2024)

**Note that Regeneron is NOT currently accepting proposals for Investigator Sponsored Studies or Research Collaborations for the Malignant Hematology Products outside the United States.**